Sales in Europe won't be affected. Allegra "D", which accounts for 25 percent of sales, won't be affected by generics. AMRI still gets royalties from generic sales of Aventis product. Allegra sales for 2006 should be minimally affected. And if something positive happens with the court case, there's a significant upside.
I agree that royalties could be even higher than today. What is the value of future BMS royalties which should be a multiple of this? With all the cash on hand and the potential to acquire companies (Nanotechnology?). Under the leadership of Dr. D�Ambra, expect great things ahead!